At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
THN102 Dosage A +2 moredrug
Likely dose
THN102 Dosage B 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
In Brief
A Phase 2 clinical trial evaluating THN102 Dosage A, THN102 Dosage B, and 1 other intervention for Parkinson Disease. Completed, enrolled 77 participants across 34 sites in 5 countries.
Detailed Summary
This is a randomized, placebo-controlled, 3-way cross-over phase IIa trial comparing two dose levels of THN102 to placebo in patients suffering from Parkinson's disease associated with excessive daytime sleepiness.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesCzechia, France, Germany, Hungary, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJul 2018
First PostedAug 2018
Primary CompletionDec 2019
Study CompletionFeb 2020
TodayJul 2026
First PostedAug 10, 2018
Enrollment StartJul 12, 2018
Primary CompletionDec 20, 2019
Study CompletionFeb 24, 2020
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.9 years ago
Interventions
THN102 Dosage Adrug
THN102 Dosages A: placebo
THN102 Dosage Bdrug
THN102 Dosage B : 200mg/2mg
THN102 Dosage Cdrug
THN102 Dosage C: 200mg/18mg